Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 7/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 7/20 | 0.48 |
| ▸ | ACE | P12821 | 6/20 | 0.48 |
| ▸ | CPA1 | P15085 | 6/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 3/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14123993 | 0.87 | MMP9 (0.47) | PSMB5MMEACE2ACECPA1 | |
| SCHEMBL14307474 | 0.84 | PSMB5 (0.46) | PSMB5MMEACE2ACECPA1 | |
| SCHEMBL24476234 | 0.82 | CTSS (0.51) | MMEACECTSSCTSKCTSB | |
| SCHEMBL14416298 | 0.82 | CYP1A2 (0.51) | MMEACE2ACECPA1CTSK | |
| SCHEMBL27334440 | 0.82 | CTSS (0.51) | MMEACECTSSCTSKCTSB | |
| SCHEMBL24899422 | 0.82 | L3MBTL1 (0.53) | PSMB5MMEACE2ACECPA1 | |
| SCHEMBL22695725 | 0.79 | CTSS (0.54) | MMEACECTSSCTSKCTSB | |
| SCHEMBL16656682 | 0.79 | CTSS (0.54) | MMEACECTSSCTSKCTSB | |
| SCHEMBL17915462 | 0.78 | MME (0.61) | MMEACE2ACECPA1MMP9 | |
| Hydrochloric Acid SCHEMBL8453081 | 0.77 | MME (0.60) | MMEACE2ACECPA1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208008-A1 | SUBSTITUTED SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY | AVENTIS PHARMACEUTICALS INC. (US) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208008-A1 | SUBSTITUTED SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY | CHUK, SRC, DSTYK | PSMB5 2746/4885MME 2024/4885ACE2 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.